Presented by Dan Roberts to the International Low Vision Support Group, February 2017) View/listen to the presentation. Those of us who are affected by vision loss often feel like we are in a vacuum, dealing alone with the physiological and emotional effects on our personal lives. We hesitate to discuss our concerns with anyone, so [Read More]
News
Annual Eye Exams For Retinopathy May Be Unnecessary For Some Type 1 Diabetics
Currently, patients who have had type 1 diabetes for 5 years are encouraged to have annual dilated retinal exams to look for possible progression to diabetic retinopathy (DR) or diabetic macular edema (DME). Both of these conditions can lead to severe vision loss and should be treated immediately. Now, a 30-year study* published in April [Read More]
Women Face Higher Risk of Blindness Than Men
Studies show there is a gender gap in eye disease. Women are more likely than men to suffer from sight-threatening conditions such as age-related macular degeneration (AMD), cataracts, and glaucoma.1 In support of Healthy Vision Month in May, the American Academy of Ophthalmology reminds women to make vision a top priority. Women make up 65 percent [Read More]
FDA Approves Lucentis® for Diabetic Retinopathy
Genentech, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 and affects [Read More]
New Sustained Delivery Method for Lucentis
Genentech, Inc. is testing a less-invasive method of delivery of their anti-VEGF drug Lucentis into the eyes of patients with wet AMD. Currently, anti-VEGF treatments require regular monthly or bi-monthly injections into the back of the eye, which can be taxing on patients’ time and stress level. The new method utilizes a timed release capsule [Read More]